Related Experiment Videos
Mn (III) hematoporphyrin. A potential MR contrast agent
P J Bohdiewicz1, D K Lavallee, R A Fawwaz
1Department of Radiology, Columbia-Presbyterian Medical Center, New York, NY 10032.
Investigative Radiology
|July 1, 1990
Summary
Manganese (III) hematoporphyrin (MnHP) shows potential as a liver MR contrast agent. While toxic at higher doses, MnHP demonstrated good in vivo stability and enhanced liver signal intensity in MR imaging.
Area of Science:
- Biochemistry
- Medical Imaging
- Toxicology
Background:
- Manganese (III) hematoporphyrin (MnHP) is a novel complex.
- Its stability, toxicity, and utility in magnetic resonance (MR) imaging require evaluation.
Purpose of the Study:
- To assess the toxicity profile of MnHP.
- To evaluate the MR imaging properties of MnHP, particularly for liver applications.
Main Methods:
- Acute and subacute toxicity tests were performed using intravenous injections of MnHP in rats.
- In vivo stability was assessed using ultraviolet-visible spectroscopy.
- MR imaging was conducted on rats injected with MnHP to measure liver-to-muscle intensity ratios and observe signal changes.
Main Results:
- No mortality was observed at doses of 13 or 19 mumols/kg, but 33% mortality occurred at 38 mumols/kg.
- Spectroscopy confirmed the in vivo stability of MnHP, with no free hematoporphyrin detected.
- A significant increase (37%) in liver-to-muscle intensity ratios was observed at 25 mumols/kg, with visual enhancement of liver signal on T1-weighted images at lower doses.
Conclusions:
- MnHP exhibits dose-dependent toxicity.
- The complex is stable in vivo.
- MnHP shows promise as an MR contrast agent for liver imaging, warranting further investigation.